SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • May 12th, 2020 • Vascular Biogenics Ltd. • Pharmaceutical preparations • New York
Contract Type FiledMay 12th, 2020 Company Industry JurisdictionThis Securities Purchase Agreement (this “Agreement”) is dated as of May 11, 2020, between Vascular Biogenics Ltd., a company organized under the laws of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
ORDINARY SHARE PURCHASE WARRANT Vascular Biogenics Ltd.Security Agreement • May 12th, 2020 • Vascular Biogenics Ltd. • Pharmaceutical preparations
Contract Type FiledMay 12th, 2020 Company IndustryTHIS ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on November 11, 2021 (the “Termination Date”), but not thereafter, to subscribe for and purchase from Vascular Biogenics Ltd., a company organized under the laws of Israel (the “Company”), up to ______ Ordinary Shares, NIS 0.01 par value (the “Ordinary Share(s)”) (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one Ordinary Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).